Decitabine

Generic Name
Decitabine
Brand Names
Dacogen, Inqovi 5 Tablet Pack
Drug Type
Small Molecule
Chemical Formula
C8H12N4O4
CAS Number
2353-33-5
Unique Ingredient Identifier
776B62CQ27
Background

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogues such as decitabine and azacitidine integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits.

Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor cedazuridine.

Indication

Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored as belonging to the intermediate-1, intermediate-2, or high-risk group in the International Prognostic Scoring System.

Associated Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Associated Therapies
-

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-12-17
Last Posted Date
2024-03-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
49
Registration Number
NCT02632721
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Mayo Clinic Cancer Center, Jacksonville, Florida, United States

🇩🇪

Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany

and more 11 locations

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

First Posted Date
2015-11-18
Last Posted Date
2023-12-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
252
Registration Number
NCT02608268
Locations
🇺🇸

Sidney Kimmel CCC At JH Sidney Kimmel CCC, Baltimore, Maryland, United States

🇺🇸

Dana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States

🇺🇸

UT M.D Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

First Posted Date
2015-08-25
Last Posted Date
2018-06-15
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
13
Registration Number
NCT02532010
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

First Posted Date
2015-07-02
Last Posted Date
2024-12-19
Lead Sponsor
BerGenBio ASA
Target Recruit Count
122
Registration Number
NCT02488408
Locations
🇩🇪

Universitätsklinikum Ulm, Ulm, Germany

🇮🇹

Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

🇩🇪

Medizinische Hochschule Hannover,Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation,, Hannover, Carl-Neuberg-Str, Germany

and more 9 locations

Prospective Study of Patients With Thrombocytopenia Following HSCT

First Posted Date
2015-07-01
Last Posted Date
2020-05-06
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
97
Registration Number
NCT02487563
Locations
🇨🇳

The First affiliated Hospital of SooChow University, Suzhou, Jiangsu, China

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2015-06-11
Last Posted Date
2018-10-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
3
Registration Number
NCT02469415
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Epigenetic Reprogramming in Relapse AML

First Posted Date
2015-04-09
Last Posted Date
2019-01-24
Lead Sponsor
Michael Burke
Target Recruit Count
3
Registration Number
NCT02412475
Locations
🇺🇸

Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

🇺🇸

Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

First Posted Date
2015-01-22
Last Posted Date
2019-11-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
148
Registration Number
NCT02343939
Locations
🇺🇸

University of Kansas Medical Center Research Institute, Inc, Fairway, Kansas, United States

🇩🇪

Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany

🇺🇸

Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath